Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Satralizumab Accepted for Review in Europe, US; Chugai Plans Japan Filing Before Year-End
Chugai Pharmaceutical said on October 30 that European and US regulators have accepted marketing applications for satralizumab (development code: SA237), an anti-IL-6 receptor humanized recycling antibody, for adult and adolescent patients with neuromyelitis optica spectrum disorder (NMOSD). The Medicines Agency…
To read the full story
Related Article
- Chugai’s Satralizumab Hits Primary Target in PIII Study
September 13, 2019
- Chugai’s Satralizumab Wins FDA Breakthrough Therapy Status
December 20, 2018
BUSINESS
- Sawai Prevails in ALS Drug Contract Appeal against Neugen
July 3, 2026
- Insilico, Takeda Ink AI Drug Discovery Deal Worth Up to US$600 Million
July 3, 2026
- Otsuka’s Voyxact Shows Two-Year Kidney Benefit in PIII IgAN Trial
July 3, 2026
- PeptiDream, NCC Start FIH Study of CLDN18.2 Radiopharmaceutical
July 3, 2026
- PeptiDream Poaches 3 EVPs to Bolster Global Expansion
July 3, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…